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ABSTRACT
Background There is uncertainty about the 
associations of angiotensive enzyme (ACE) inhibitor and 
angiotensin receptor blocker (ARB) drugs with COVID-19 
disease. We studied whether patients prescribed these 
drugs had altered risks of contracting severe COVID-19 
disease and receiving associated intensive care unit (ICU) 
admission.
Methods This was a prospective cohort study using 
routinely collected data from 1205 general practices in 
England with 8.28 million participants aged 20–99 years. 
We used Cox proportional hazards models to derive 
adjusted HRs for exposure to ACE inhibitor and ARB 
drugs adjusted for sociodemographic factors, concurrent 
medications and geographical region. The primary 
outcomes were: (a) COVID-19 RT- PCR diagnosed disease 
and (b) COVID-19 disease resulting in ICU care.
Findings Of 19 486 patients who had COVID-19 
disease, 1286 received ICU care. ACE inhibitors were 
associated with a significantly reduced risk of COVID-19 
disease (adjusted HR 0.71, 95% CI 0.67 to 0.74) 
but no increased risk of ICU care (adjusted HR 0.89, 
95% CI 0.75 to 1.06) after adjusting for a wide range of 
confounders. Adjusted HRs for ARBs were 0.63 (95% CI 
0.59 to 0.67) for COVID-19 disease and 1.02 (95% CI 
0.83 to 1.25) for ICU care.
There were significant interactions between ethnicity and 
ACE inhibitors and ARBs for COVID-19 disease. The risk 
of COVID-19 disease associated with ACE inhibitors was 
higher in Caribbean (adjusted HR 1.05, 95% CI 0.87 
to 1.28) and Black African (adjusted HR 1.31, 95% CI 
1.08 to 1.59) groups than the white group (adjusted HR 
0.66, 95% CI 0.63 to 0.70). A higher risk of COVID-19 
with ARBs was seen for Black African (adjusted HR 1.24, 
95% CI 0.99 to 1.58) than the white (adjusted HR 0.56, 
95% CI 0.52 to 0.62) group.
Interpretation ACE inhibitors and ARBs are associated 
with reduced risks of COVID-19 disease after adjusting 
for a wide range of variables. Neither ACE inhibitors nor 
ARBs are associated with significantly increased risks of 
receiving ICU care. Variations between different ethnic 
groups raise the possibility of ethnic- specific effects of 
ACE inhibitors/ARBs on COVID-19 disease susceptibility 
and severity which deserves further study.
INTRODUCTION
The first cases of infection caused by severe acute 
respiratory syndrome coronavirus 2 (SARS- CoV-2) 
(COVID-19) in the UK were confirmed on 24 
January 2020. Since then the disease has spread 
rapidly through the population. There are no 
vaccines, preventative or curative treatments for 
COVID-19 disease and only one possible disease- 
modifying treatment1 so the government has used 
social distancing as a population- level intervention 
to limit the rate of increase in cases.
Case series of confirmed COVID-19 have iden-
tified age,2 sex,3 comorbidities2 4 and ethnicity5 as 
potentially important risk factors for susceptibility 
to infection, hospitalisation or death due to infec-
tion. In addition, chronic use of some medications 
at the time of exposure has been suggested as a 
potential risk factor for infection or severe adverse 
outcomes due to infection,6 although the evidence 
is currently too limited to confirm or refute these 
concerns.7 Understanding this chronic medication 
use is important because medications could be modi-
fied in individuals or at a population scale to alter 
the likelihood of infection or adverse outcomes. 
Furthermore, associations between medications 
and improved outcomes, if confirmed from large 
cohorts, could provide a basis for rapid prioritisa-
tion in prospective randomised clinical trials, and 
might provide important insights into disease mech-
anisms and pathogenesis.
SARS- CoV-1 and SARS- CoV-2, which have been 
responsible for the SARS epidemic and for the 
COVID-19 pandemic, respectively, interface with 
the renin- angiotensin- aldosterone system (RAAS) 
through ACE2, an enzyme that modulates the 
effects of the RAAS but is also the primary receptor 
for both SARS viruses. The interaction between the 
SARS viruses and ACE2 may be one determinant of 
their infectivity, and there are concerns that RAAS 
inhibitors may change ACE2 expression and hence 
COVID-19 virulence. This hypothesis has been 
extensively reviewed.7
ACE inhibitors and angiotensin receptor blocker 
(ARB) drugs are recommended by the National 
Institute for Health and Care Excellence as first- 
line treatment for patients under 55 years of age 
with hypertension and second- line treatment for 
those over 55 years of age and for those of African 
descent.8 ACE inhibitors are also widely used to 
treat congestive cardiac failure. Uncertainty around 
possible associations of these drugs with COVID-19 
disease, and the subsequent risk that patients might 
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stop taking these drugs of proven effectiveness, has led to regu-
latory and professional bodies issuing statements urging patients 
to keep taking their regular medications.9
Although several studies have considered the effect in hospital-
ised patients of drugs acting on the renin- angiotensin on disease 
course,6 10 11 none has looked at population use of these drugs 
to determine if they modulate susceptibility. We report a large, 
population- based study where we examined the drug histories of 
approximately 20% of all patients tested positive for coronavirus 
in England to determine if there was an independent association 
between ACE inhibitor and ARB drug prescription and severe 
COVID-19 disease susceptibility and progression.
METHODS
Study design, sources of data and participants
We undertook a large, open cohort study of all patients aged 
20–99 years registered with 1205 general practices in England 
contributing to the QResearch database (V.44, uploaded 24 
March 2020) linked to COVID-19 RT- PCR test records (updated 
until 26 April 2020) and with intensive care records (updated 
until 27 April 2020). The protocol is published.12
Primary care data and linked databases
We included general practices in England contributing to the 
QResearch database from which current data were available. 
QResearch is a high- quality research database established 
in 2002, which has been extensively used for pharmaco- 
epidemiological research.13 QResearch is the largest and most 
representative General Practitioner (GP) practice research data-
base nationally.14
Two national databases were linked to QResearch. The first 
was the national registry of COVID-19 RT- PCR test positive 
results held by Public Health England (PHE). Since COVID-19 
is a notifiable disease, laboratories in England are required to 
send results of all tests to PHE. At the time of analysis, 106 529 
positive COVID-19 test results were available from 106 507 
individuals in England, until 26 April 2020, of whom 104 665 
were aged 20–99 years. Of these, 19 486 (18.6%) were linked to 
QResearch patients.
The second linked database was the Intensive Care National 
Audit and Research Centre (ICNARC) Case Mix Programme 
(CMP) database. This is a high- quality, clinical research data-
base which includes contemporaneous data from 285 ICUs in 
England, Wales and Northern Ireland and is widely used for 
cohort studies, comparative audit and outcome data ascertain-
ment for randomised clinical trials.15 16 As of 28 April 2020, 
there were 6968 patients admitted for ICU care with COVID-19 
disease, of whom 6963 were aged 20–99 years. Of these, 1286 
(18.5%) were linked to QResearch.
Participants
We identified a cohort consisting of all patients aged 20–99 years 
who were fully registered with the GP practices on the start date 
(1 January 2020). Patients entered the cohort on this date and 
were censored at the earliest of the date of death, leaving the GP 
practice, the study end date (27 April 2020) or occurrence of the 
relevant outcomes of interest. We used all the relevant patients 
on the pooled database to maximise power and to enhance 
generalisability of the results.
Outcomes
During our study period, over 98.6% of all COVID-19 RT- PCR 
tests in England were undertaken in a hospital setting for 
symptomatic patients sufficiently unwell to warrant hospital 
assessment and admission.
Our main outcomes for these analyses were:
1. COVID-19 RT- PCR test positive disease.
2. COVID-19- related admission for ICU care.
Primary exposure variables
We had two main exposures of interest:
1. ACE inhibitors.
2. ARBs.
We classified a patient as having had exposure to either 
medication if they had three or more prescriptions, including a 
prescription issued in the 90 days preceding cohort entry.
Explanatory variables
We extracted data from the GP record for explanatory and 
potential confounding variables including variables with some 
evidence of being risk factors for COVID-19 disease or severe 
disease as measured by ICU admission and variables likely to 
influence prescribing of ACE inhibitors and ARB medications. 
We used the latest information recorded in the GP record on or 
before study entry as follows:
1. Age (<40; 40–49; 50–59; 60–69; 70–79; 80+ years).
2. Ethnicity (nine categories—white and not recorded, Indian, 
Pakistani, Bangladeshi, other Asian, Black Caribbean, Black 
African, Chinese, other)
3. Deprivation quintiles (as measured by the Townsend score 
where quintile 1 is the most affluent and 5 is the most 
deprived).
4. Geographical region within England, categorised into 10 
groups.
5. Body mass index (kg/m2), categorised into five categories—
underweight (<20 kg/m2); normal weight (20–24.9 kg/m2); 
overweight (25–29.9 kg/m2); obese (30–34.9 kg/m2); severe-
ly obese (>35 kg/m2).
6. Smoking status in five categories—never- smoker; ex- 
smoker; light smoker (1–9 cigarettes/day); moderate smoker 
(10–19 cigarettes/day); heavy smoker (20+ cigarettes/ day).
7. GP recorded diagnosis of type 1 or type 2 diabetes.
8. GP recorded diagnosis of cardiovascular disease.
9. GP recorded diagnosis of congestive cardiac failure.
10. GP recorded diagnosis of hypertension.
11. GP recorded diagnosis of atrial fibrillation.
12. GP recorded diagnosis of asthma.
13. GP recorded diagnosis of chronic obstructive pulmonary 
disease.
14. GP recorded diagnosis of chronic kidney disease (CKD 
stage 3, 4 or 5).
We also extracted medication use for the following classes of 
drugs as potential confounding variables. We focused on classes 
of drugs rather than individual drugs to ensure adequate power. 
We classified patients as exposed using the same definitions as 
ACE inhibitors and ARBs.
1. Drugs to treat type 2 diabetes including sulfonylureas, bigu-
anides and other drugs (thiazolidinediones, gliptins, sodium 
glucose co- transporter 2 inhibitors, glucagon- like peptide-1 
receptor agonists, meglitinides).
2. Anticoagulant drugs (warfarin and direct oral anticoagu-
lants).
3. Antiplatelet drugs.
4. Calcium channel blocking drugs.
5. Thiazides.
6. Potassium- sparing diuretics.
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7. Statins.
Statistical analyses
After conducting univariable analyses, we conducted a multivari-
able analysis based on patients with complete data. We then used 
multiple imputation with chained equations to replace missing 
values for ethnicity, body mass index and smoking status and 
used these values in our main analyses.17 We included all expo-
sure and explanatory variables in the imputation model, along 
with the Nelson- Aalen estimator of the baseline cumulative 
hazard, and the outcome indicator. We carried out five impu-
tations. We used Cox’s proportional hazards models to estimate 
adjusted HRs for ACE inhibitors and ARBs adjusting for the 
confounders. We tested for interactions between ACE inhibitors, 
ARBs and ethnicity.
We undertook several sensitivity analyses. To further reduce 
indication biases, additional analyses restricted to patients with 
hypertension or heart failure to directly compare risks for ACE 
inhibitors and ARBs with other antihypertensive drugs. We also 
undertook analyses adjusted for the number of antihypertensive 
drugs as a proxy for severity of hypertension (untreated hyper-
tension; monotherapy; dual therapy; triple or more therapy). 
Lastly, we changed the definition of exposure to requiring a 
prescription within the last 30 days prior to cohort entry. We 
used p<0.01 (two- tailed) to determine statistical significance, to 
take account of multiple testing.
Patient and public involvement
Patient representatives from the QResearch Advisory Board 
have advised the whether to undertake this research, on the 
data linkage, public interest and likely public benefit resulting 
from the study, dissemination of studies using QResearch data, 
including the use of lay summaries describing the research and 
its findings.
RESULTS
Overall study population
One thousand two hundred five QResearch practices were 
included in our analysis. Of the 10 594 500 patients registered 
on 1 January 2020, 8 275 949 were aged between 20 and 99 
years. Of these, 19 486 (0.24%) had a COVID-19 RT- PCR posi-
tive result and 1286 were admitted to an ICU.
Baseline characteristics
Table 1 shows the baseline characteristics of the overall cohort 
consisting of 8 275 949 patients. The median age was 47 years 
(IQR 33–62); self- assigned ethnicity was recorded in 6 691 660 
(80.9%). A total of 645 577 patients (7.8% of 8 275 949) were 
currently prescribed an ACE inhibitor and 308 881 (3.7%) were 
currently prescribed an ARB drug. Table 2 shows the proportions 
of patients prescribed ACE inhibitors and ARBs by ethnicity and 
other characteristics.
Figure 1A and B show adjusted HRs for each outcome based 
on the multiply- imputed data. Figure 2A and B show the same 
for the complete case analysis.
Associations of each outcome with the primary exposures of 
interest: ACE inhibitor and ARB medication
ACE inhibitors were associated with a significantly reduced risk 
of COVID-19 disease requiring hospital admission (adjusted HR 
0.71, 95% CI 0.67 to 0.74) but were not significantly associ-
ated with risk of ICU care (adjusted HR 0.89, 95% CI 0.75 to 
1.06) after adjusting for a wide range of confounders. Adjusted 
Table 1 Baseline characteristics of men and women aged 20–99 
years registered with QResearch practices on 1 January 2020 and 
characteristics of patients with each of the two primary outcomes
Category
Total population 
(column %)
COVID-19 
positive 
(column %)
COVID-19 ICU 
admission 
(column %)
Total population 8 275 949 19 486 1286
Male 4 115 973 (49.73) 9376 (48.12) 940 (73.09)
Age (years)       
  Mean age (SD) 48.47 (18.41) 62.18 (20.84) 59.19 (12.52)
  20–39 3 135 980 (37.89) 3487 (17.89) 95 (7.39)
  40–49 1 399 562 (16.91) 2474 (12.70) 159 (12.36)
  50–59 1 386 093 (16.75) 2927 (15.02) 366 (28.46)
  60–69 1 037 077 (12.53) 2462 (12.63) 387 (30.09)
  70–79 802 224 (9.69) 2734 (14.03) 242 (18.82)
  80+ years 515 013 (6.22) 5402 (27.72) 37 (2.88)
Material deprivation       
  Quintile 1 (most affluent) 1 877 761 (22.69) 3834 (19.68) 214 (16.64)
  Quintile 2 1 819 942 (21.99) 3970 (20.37) 215 (16.72)
  Quintile 3 1 671 924 (20.20) 4205 (21.58) 237 (18.43)
  Quintile 4 1 490 725 (18.01) 3846 (19.74) 248 (19.28)
  Quintile 5 (most deprived) 1 415 597 (17.10) 3631 (18.63) 372 (28.93)
  Ethnicity recorded 6 691 660 (80.86) 16 379 (84.06) 1111 (86.39)
  White/not recorded 6 960 062 (84.10) 14 976 (76.86) 788 (61.28)
  Indian 228 467 (2.76) 847 (4.35) 66 (5.13)
  Pakistani 147 397 (1.78) 399 (2.05) 48 (3.73)
  Bangladeshi 110 368 (1.33) 256 (1.31) 44 (3.42)
  Other Asian 146 174 (1.77) 661 (3.39) 70 (5.44)
  Caribbean 93 949 (1.14) 557 (2.86) 59 (4.59)
  Black African 199 200 (2.41) 812 (4.17) 106 (8.24)
  Chinese 82 984 (1.00) 87 (0.45) 12 (0.93)
  Other ethnic group 307 348 (3.71) 891 (4.57) 93 (7.23)
Geographical region
  East Midlands 216 535 (2.62) 238 (1.22) 13 (1.01)
  East of England 296 236 (3.58) 562 (2.88) 19 (1.48)
  London 2 080 923 (25.14) 6059 (31.09) 588 (45.72)
  North East 194 027 (2.34) 600 (3.08) 26 (2.02)
  North West 1 471 787 (17.78) 4042 (20.74) 220 (17.11)
  South Central 1 104 114 (13.34) 2600 (13.34) 123 (9.56)
  South East 927 208 (11.20) 1982 (10.17) 119 (9.25)
  South West 899 722 (10.87) 1055 (5.41) 52 (4.04)
  West Midlands 781 297 (9.44) 1759 (9.03) 95 (7.39)
  Yorkshire and Humber 304 100 (3.67) 589 (3.02) 31 (2.41)
Smoking status     
  Never smoker 4 745 455 (57.34) 12 036 (61.77) 791 (61.51)
  Ex- smoker 1 774 275 (21.44) 5715 (29.33) 427 (33.20)
  Light smoker 1 109 154 (13.40) 1102 (5.66) 47 (3.65)
  Moderate smoker 213 629 (2.58) 155 (0.80) 7 (0.54)
  Heavy smoker 98 748 (1.19) 97 (0.50) 2 (0.16)
  Smoking not recorded 334 688 (4.04) 381 (1.96) 12 (0.93)
Body mass index (BMI)     
  BMI <20 kg/m2 543 347 (6.57) 1076 (5.52) 13 (1.01)
  BMI 20–24.99 kg/m2 2 438 268 (29.46) 4913 (25.21) 165 (12.83)
  BMI 25–29.99 kg/m2 2 344 187 (28.33) 5925 (30.41) 410 (31.88)
  BMI 30–34.99 kg/m2 1 090 042 (13.17) 3435 (17.63) 341 (26.52)
  BMI 35+ kg/m2 619 487 (7.49) 2409 (12.36) 294 (22.86)
  BMI not recorded 1 240 618 (14.99) 1728 (8.87) 63 (4.90)
Concurrent morbidity     
  Chronic renal disease 338 693 (4.09) 3442 (17.66) 152 (11.82)
  Asthma 1 089 645 (13.17) 2764 (14.18) 178 (13.84)
  COPD 195 115 (2.36) 1421 (7.29) 46 (3.58)
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HRs for ARBs were 0.63 (95% CI 0.59 to 0.67) for COVID-19 
disease and 1.02 (95% CI 0.83 to 1.25) for ICU care. The results 
were similar, when the proxy measure of hypertension severity 
was included with adjusted HRs of COVID-19 disease for ACE 
inhibitors of 0.87 (95% CI 0.72 to 1.05) and 0.82 (0.68 to 0.99) 
for ARB.
The results were similar when restricted to patients who had 
either hypertension or congestive cardiac failure. The adjusted 
HRs of COVID-19 disease requiring hospital admission associ-
ated with ACE inhibitors in this group was 0.69 (95% CI 0.65 to 
0.73) and ICU admission was 0.96 (95% CI 0.78 to 1.16). The 
corresponding adjusted HRs for ARBs were 0.65 (95% CI 0.61 
to 0.69) and 1.14 (95% CI 0.91 to 1.42).
There were significant interactions with ethnicity for ACE 
inhibitors and ARB (both p<0.001) for the COVID-19 RT- PCR 
diagnosed disease outcome. Table 3 shows the adjusted HRs for 
ACE inhibitor and ARB use for each of the ethnic groups. For 
ACE inhibitors the risks of COVID-19 disease were significantly 
higher in the Caribbean and Black African groups than the white 
group, with a significantly increased risk in the Black African 
group (adjusted HR 1.31, 95% CI 1.08 to 1.59), although the 
CIs were wide in the non- white ethnic groups. The risks associ-
ated with ARB use were significantly higher in the other Asian, 
Black African, Chinese and other ethnic group than the white 
group.
Association of each outcome with age, sex, deprivation and 
ethnicity
While men were at no greater risk of having COVID-19 diagnosed 
disease requiring hospital admission than women (adjusted HR 
1.02, 95% CI 0.99 to 1.05), they had a threefold increased risk of 
Category
Total population 
(column %)
COVID-19 
positive 
(column %)
COVID-19 ICU 
admission 
(column %)
  Cardiovascular disease 433 631 (5.24) 3552 (18.23) 141 (10.96)
  Atrial fibrillation 201 911 (2.44) 1870 (9.60) 41 (3.19)
  Congestive cardiac failure 97 118 (1.17) 1211 (6.21) 25 (1.94)
  Type 1 diabetes 39 094 (0.47) 208 (1.07) 23 (1.79)
  Type 2 diabetes 536 516 (6.48) 4027 (20.67) 379 (29.47)
  Hypertension diagnosis 1 414 021 (17.09) 7585 (38.93) 584 (45.41)
  No medication 256 762 (3.10) 1804 (9.26) 93 (7.23)
  Monotherapy 773 675 (9.35) 3754 (19.27) 249 (19.36)
  Dual therapy 516 178 (6.24) 2540 (13.03) 215 (16.72)
  Triple therapy 190 856 (2.31) 1005 (5.16) 119 (9.25)
Long- term medication       
  ACE inhibitor 645 577 (7.80) 2864 (14.70) 266 (20.68)
  ARB 308 881 (3.73) 1417 (7.27) 154 (11.98)
  Beta- blockers 525 149 (6.35) 3185 (16.35) 170 (13.22)
  Calcium channel blockers 654 171 (7.90) 3293 (16.90) 353 (27.45)
  Other diabetes drugs 151 074 (1.83) 1183 (6.07) 148 (11.51)
  Sulfonylureas 98 908 (1.20) 808 (4.15) 110 (8.55)
  Biguanides 328 387 (3.97) 2135 (10.96) 262 (20.37)
  Anticoagulants 207 061 (2.50) 1872 (9.61) 43 (3.34)
  Antiplatelets 410 816 (4.96) 3049 (15.65) 172 (13.37)
  Statins 1 073 039 (12.97) 5616 (28.82) 487 (37.87)
  Thiazides 220 143 (2.66) 803 (4.12) 96 (7.47)
  Potassium- sparing diuretics 46 825 (0.57) 417 (2.14) 11 (0.86)
Values are number (%) of patients unless indicated otherwise.
ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; ICU, 
intensive care unit.
Table 1 Continued Table 2 Numbers and proportions of patients taking ACE inhibitor or 
ARB medication according to patient characteristics
Category
Number in 
category
Prescribed ACE 
inhibitor (row %)
Prescribed ARB 
(row %)
Total population 8 275 949 645 577 (7.80) 308 881 (3.73)
Male 4 115 973 375 509 (9.12) 145 181 (3.53)
Female 4 159 976 270 068 (6.49) 163 700 (3.94)
Age (years)     
  20–39 3 135 980 10 921 (0.35) 3635 (0.12)
  40–49 1 399 562 44 117 (3.15) 14 746 (1.05)
  50–59 1 386 093 125 971 (9.09) 46 885 (3.38)
  60–69 1 037 077 163 430 (15.76) 74 343 (7.17)
  70–79 802 224 176 435 (21.99) 95 393 (11.89)
  80+ 515 013 124 703 (24.21) 73 879 (14.35)
Material deprivation     
  Quintile 1 (most affluent) 1 877 761 177 329 (9.44) 92 484 (4.93)
  Quintile 2 1 819 942 161 223 (8.86) 80 220 (4.41)
  Quintile 3 1 671 924 130 505 (7.81) 60 006 (3.59)
  Quintile 4 1 490 725 101 993 (6.84) 44 660 (3.00)
  Quintile 5 (most deprived) 1 415 597 74 527 (5.26) 31 511 (2.23)
Ethnicity     
  White/not recorded 6 960 062 575 787 (8.27) 264 990 (3.81)
  Indian 228 467 14 185 (6.21) 9936 (4.35)
  Pakistani 147 397 10 198 (6.92) 5656 (3.84)
  Bangladeshi 110 368 8189 (7.42) 4134 (3.75)
  Other Asian 146 174 8000 (5.47) 5259 (3.60)
  Caribbean 93 949 7478 (7.96) 5358 (5.70)
  Black African 199 200 9379 (4.71) 6017 (3.02)
  Chinese 82 984 1460 (1.76) 1112 (1.34)
  Other ethnic group 307 348 10 901 (3.55) 6419 (2.09)
Geographical region     
  East Midlands 216 535 14 004 (6.47) 6016 (2.78)
  East of England 296 236 24 270 (8.19) 11 998 (4.05)
  London 2 080 923 112 569 (5.41) 58 961 (2.83)
  North East 194 027 17 597 (9.07) 6370 (3.28)
  North West 1 471 787 137 043 (9.31) 61 705 (4.19)
  South Central 1 104 114 89 462 (8.10) 42 668 (3.86)
  South East 927 208 79 871 (8.61) 43 932 (4.74)
  South West 899 722 75 767 (8.42) 32 850 (3.65)
  West Midlands 781 297 70 613 (9.04) 33 605 (4.3)
  Yorkshire and Humber 304 100 24 381 (8.02) 10 776 (3.54)
Smoking status     
  Never smoker 4 745 455 335 769 (7.08) 181 411 (3.82)
  Ex- smoker 1 774 275 227 398 (12.82) 103 363 (5.83)
  Light smoker 1 109 154 62 039 (5.59) 18 364 (1.66)
  Moderate smoker 213 629 11 542 (5.40) 3332 (1.56)
  Heavy smoker 98 748 7929 (8.03) 2011 (2.04)
  Smoking not recorded 334 688 900 (0.27) 400 (0.12)
Body mass index (BMI)     
  BMI <20 kg/m2 543 347 13 050 (2.40) 5153 (0.95)
  BMI 20–24.99 kg/m2 2 438 268 115 952 (4.76) 50 968 (2.09)
  BMI 25–29.99 kg/m2 2 344 187 231 282 (9.87) 109 202 (4.66)
  BMI 30–34.99 kg/m2 1 090 042 158 175 (14.51) 79 933 (7.33)
  BMI 35+ kg/m2 619 487 108 568 (17.53) 55 489 (8.96)
  BMI not recorded 1 240 618 18 550 (1.50) 8136 (0.66)
Concurrent morbidity     
  Chronic renal disease 338 693 103 643 (30.60) 65 255 (19.27)
  Asthma 1 089 645 83 948 (7.70) 4927 (4.52)
  COPD 195 115 43 288 (22.19) 21 063 (10.80)
  Cardiovascular disease 433 631 165 415 (38.15) 71 472 (16.48)
  Atrial fibrillation 201 911 61 332 (30.38) 32 330 (16.01)
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ICU admission despite adjustment for confounders (figure 1B). 
People from the most deprived areas had an increased risk of 
COVID-19 disease and ICU admission. There were regional 
variations in the risk of COVID-19 disease and ICU admission, 
the South West had the lowest risk of both outcomes, the North 
East had the highest risk of COVID-19 disease and London had 
the highest risk of ICU admission.
Overall, compared with the white ethnic group, all other 
ethnic groups except Chinese and Bangladeshi groups were asso-
ciated with a significantly increased risk of COVID-19 disease. 
Highest risks were found for the other Asian group who had a 
2.1- fold increased risk; Black African (1.8- fold increased risk); 
Black Caribbean (1.71- fold increased risk) and Indian (1.61- fold 
increased risk) compared with the white group. The compar-
ative risk of ICU admission in these ethnic groups was even 
higher. Compared with the white group, all other ethnic groups 
had twofold to threefold higher risks of ICU admission, but 
smaller numbers of people in these groups led to some imprecise 
estimates.
Association of each outcome with category of body mass 
index
The risks of COVID-19 disease and of ICU admission were 
higher in those with increasing BMI. The most pronounced 
gradient was for ICU admission, where being obese was asso-
ciated with a 2.6- fold increased risk and severe obesity with 
Category
Number in 
category
Prescribed ACE 
inhibitor (row %)
Prescribed ARB 
(row %)
  Congestive cardiac failure 97 118 43 746 (45.04) 21 637 (22.28)
  Type 1 diabetes 39 094 8316 (21.27) 2989 (7.65)
  Type 2 diabetes 536 516 193 155 (36.00) 88 308 (16.46)
  Hypertension diagnosis 1 414 021 536 002 (37.91) 274 784 (19.43)
  Monotherapy 773 675 230 565 (29.80) 105 921 (13.69)
  Dual therapy 516 178 293 187 (56.80) 138 397 (26.81)
  Triple therapy 190 856 121 825 (63.83) 64 563 (33.83)
  Long- term medication     
  ACE inhibitor 645 577   4119 (0.64)
  ARB 308 881 4119 (1.33)   
  Beta- blockers 525 149 189 691 (36.12) 86 126 (16.40)
  Calcium channel blockers 654 171 241 203 (36.87) 119 143 (18.21)
  Other diabetes drugs 151 074 65 933 (43.64) 29 245 (19.36)
  Sulfonylureas 98 908 43 836 (44.32) 18 591 (18.80)
  Biguanides 328 387 135 263 (41.19) 57 509 (17.51)
  Anticoagulants 207 061 66 374 (32.06) 33 889 (16.37)
  Antiplatelets 410 816 169 770 (41.33) 73 938 (18.00)
  Statins 1 073 039 388 769 (36.23) 173 983 (16.21)
  Thiazides 220 143 96 311 (43.75) 55 142 (25.05)
  Potassium- sparing diuretics 46 825 20 660 (44.12) 11 807 (25.22_
ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease.
Table 2 Continued
Figure 1 The adjusted HRs along with 95% CIs for (A) the outcome of a positive COVID-19 RT- PCR test and (B) the outcome of admission to an 
intensive care unit (ICU), for all the variables studied based on multiple imputed data. BMI, body mass index; COPD, chronic obstructive pulmonary 
disease.
copyright.
 o
n
 August 5, 2020 at G
reenfield M
edical Library Periodicals. Protected by
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2020-317393 on 31 July 2020. Downloaded from 
6 Hippisley- Cox J, et al. Heart 2020;0:1–9. doi:10.1136/heartjnl-2020-317393
Special populations
a 4.4- fold increased risk compared with the normal weight 
group. This was after adjustment for all other variables shown 
in figure 1B.
Association of each outcome with smoking status
There was a small increased risk of both adverse outcomes 
among ex- smokers compared with never- smokers. We observed 
a markedly decreased risk of both COVID-19 disease and ICU 
admission in smokers. The apparent protective association was 
greatest for heavy and moderate smokers and most markedly 
on the risk of ICU admission which was 88% lower in heavy 
smokers compared with non- smokers (figure 1B).
Association of each outcome with comorbidity and 
concurrent medication
Each of the comorbidities included in the analysis was associ-
ated with an increased risk of COVID-19 disease. However, only 
CKD, hypertension, type 1 and type 2 diabetes were significantly 
associated with an increased risk of ICU admission.
Figure 1A shows significantly increased risks of COVID-19 
disease associated with anticoagulants, antiplatelets, other 
diabetes drugs; significantly decreased risks of 10% for statins, 
30% for thiazides and 8% for calcium channel blockers and no 
significant association for biguanides, beta- blockers or sulfony-
lureas. For ICU admission there was a significantly increased risk 
Figure 2 The adjusted HRs along with 95% CIs for (A) the outcome of a positive COVID-19 RT- PCR test and (B) the outcome of admission to 
an intensive care unit (ICU), for all the variables studied based on the completed case analysis. BMI, body mass index; COPD, chronic obstructive 
pulmonary disease.
Table 3 Adjusted HRs (95% CI) for risk of COVID-19 positive test 
associated with ACE inhibitor and ARB exposure by ethnic group
ACE inhibitor
P value
ARB
P value
Adjusted HR 
(95% CI)
Adjusted HR 
(95% CI)
White 0.66 (0.63 to 
0.70)
<0.001 0.56 (0.52 to 
0.62)
<0.001
Indian 0.74 (0.61 to 
0.90)
0.003 0.66 (0.52 to 
0.82)
<0.001
Pakistani 0.83 (0.64 to 
1.09)
0.182 0.78 (0.57 to 
1.06)
0.114
Bangladeshi 0.97 (0.72 to 
1.31)
0.847 0.74 (0.49 to 
1.13)
0.164
Other Asian 0.81 (0.64 to 
1.03)
0.084 0.96 (0.73 to 
1.23)
0.726
Caribbean 1.05 (0.87 to 
1.28)
0.480 0.70 (0.53 to 
0.92)
0.010
Black African 1.31 (1.08 to 
1.59)
0.005 1.24 (0.99 to 
1.58)
0.062
Chinese 0.73 (0.30 to 
1.79)
0.575 1.53 (0.77 to 
3.01)
0.223
Other ethnic group 0.82 (0.67 to 
1.05)
0.122 1.09 (0.86 to 
1.39)
0.475
HRs are comparing risks of COVID-19 in users versus non- users of ACE inhibitor and ARB, 
and are adjusted for age, sex, deprivation, geographical region, comorbidities (including 
hypertension included as a binary variable) and other medications listed in table 1.
ARB, angiotensin receptor blocker.
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for calcium channel blockers, but no significant associations with 
the other drugs (at p<0.01).
DISCUSSION
Summary of key results
In this very large population- based study, ACE inhibitor and ARB 
prescriptions were associated with a reduced risk of COVID-19 
RT- PCR positive disease, having adjusted for a wide range of 
demographic factors, potential comorbidities and other medica-
tion. There was no evidence of an increased or reduced risk of 
ICU admission with either drug.
There were marked variations in risk of COVID-19 disease 
and of requiring ICU admission by ethnic group, with highest 
rates among Black, Asian, and minority ethnic (BAME) groups. 
This association is important and adds to existing knowledge18 
since it is not explained by age, sex, deprivation, geographical 
region or several comorbidities and intercurrent medications 
included in our analysis.
Comparisons with the literature
To date, published studies reporting associations between chronic 
medication with ACE inhibitor or ARB drugs and COVID-19 
infections are limited to hospitalised patients6 10 11 19 or those 
attending a hospital clinic.20 This allows the study of drug treat-
ment effects on the in- hospital disease course but not effects on 
disease susceptibility since there is no information on medication 
use in the uninfected or less severely infected population. Most 
in- hospital studies are relatively small containing low numbers 
of patients or ACE inhibitors of ARBs in comparison to our 
study. However, two6 19 were able to correct for the confounding 
effects of age, gender, comorbidities and in- hospital medica-
tions. In one study of 1128 patients with hypertension of whom 
188 were taking ACE inhibitors/ARB,6 in- hospital use of ACE 
inhibitor or ARB medication was associated with a lower risk of 
all- cause in- hospital mortality (adjusted HR 0.42; 95% CI 0.19 
to 0.92; p=0.03). In the larger 8910 patient study (770 taking 
ACE inhibitors and 556 ARBs), ACE inhibitors were associated 
with reduced in- hospital mortality (2.1% vs 6.1%; OR 0.33; 
95% CI 0.20 to 0.54) but ARBs were not (6.8% vs 5.7%; OR 
1.23; 95% CI 0.87 to 1.74).19 Conversely, there was no evidence 
of reduced risk in outcomes in patients receiving ACE inhibitor 
and ARB drugs in initial reports from New York.11
In our study, prior prescription of ACE inhibitor and ARB 
drugs did not have a significant effect on the risk of patients 
developing COVID-19 disease severe enough to require ICU 
care. In contrast, we found that previously prescribed ACE 
inhibitor and ARB drugs are associated with the likelihood of an 
individual testing positive for COVID-19 in a hospital setting. 
The effect was similar for both drug classes. This may indicate 
that drug treatment at the time of exposure altered susceptibility 
to COVID-19 infection and/or altered the likelihood of an infec-
tion progressing to the point where testing is sought. It is also 
possible that this reflects a ‘healthy user’ selection bias. There are 
no other population- based studies of ACE inhibitor/ARB use and 
COVID-19 infection. Losartan is already being tested in a clin-
ical trial as a treatment of COVID-19 infection.21 Its efficacy may 
depend on the context in which it is tested. Since the recommen-
dations for treatment of hypertension differ according to ethnic 
groups and age, we considered the possibility that these factors 
might contribute to the observed association between ACE 
inhibitor or ARB use and COVID-19 disease or severity. ACE 
inhibitors are recommended as first- line treatment for hyper-
tension, whereas calcium channel blockers are recommended 
in patients of black ethnic origin.8 Indeed, there were signifi-
cant interactions between ethnicity, ACE inhibitor and ARBs for 
COVID-19 disease. ARBs were significantly less protective in the 
other Asian, Black African, Chinese and other ethnic group than 
the white group. ACE inhibitors appeared less protective in the 
Caribbean than the white group and were associated with an 
increased risk of COVID-19 disease in the Black African group. 
This raises the possibility of ethnic- specific effects of ACE inhib-
itors/ARBs on COVID-19 disease susceptibility and severity or 
unmeasured confounding. However, as numbers were relatively 
small in the non- white ethnic groups so CIs were wide, caution 
is needed in interpreting these results.
Studies of patients hospitalised with COVID-19 have noted 
a greater than expected number of patients with hypertension,2 
and hypertension appears to be a risk factor for more severe 
COVID-19 disease across many studies.4 In our study, hyperten-
sion was a risk factor for being tested positive for COVID-19 in a 
hospital setting independent of ACE inhibitor and ARB treatment, 
but was only modestly associated with likelihood of ICU admis-
sion. We found an expected association with obesity, with those 
who are obese or severely obese having higher risk of COVID-19 
disease and ICU admission. However, we have reported a coun-
terintuitive finding for smoking, with light, moderate and heavy 
smokers having a lower risk for both COVID-19 disease and 
ICU admission. One systematic review concluded on the basis of 
limited evidence either there is no difference in risk by smoking 
status or that there is an increased risk in smokers.22 However, 
our data are consistent with very low rates of smoking seen in 
patients presenting with COVID-19 in Wuhan23 and similar data 
from the USA24 and with the findings of a more limited anal-
ysis of patients with COVID-19 in France.25 This may reflect a 
general immunomodulatory effect, a mechanism that is thought 
to explain the lower incidence of sarcoidosis, extrinsic allergic 
alveolitis and ulcerative colitis in current smokers.26 27 Alterna-
tively, smoking may cause increased ACE2 mRNA expression in 
human lung much as ACE inhibitors or ARBs are believed to, 
suggesting a possible common protective mechanism for severe 
COVID-19 disease.28 Additional possible mechanisms include 
a direct protective effect of nicotinic receptor stimulation29 or 
an association of smoking with another protective factor. This 
finding arose when including smoking status as a confounder and 
should be interpreted cautiously. Further studies are required to 
verify the apparent protective association, determine whether 
it is independent of other risk factors, and investigate potential 
mechanisms.
Strengths
We have used two high- quality, established large validated 
research databases (QResearch and ICNARC CMP) and linked 
them to the national register of COVID-19 test results. Our 
study is observational with strengths and inherent limitations 
since the data were collected as part of routine NHS care. Key 
strengths include the use of high- quality, established validated 
databases, size, representativeness, lack of selection, recall 
and respondent bias. UK general practices have good levels of 
accuracy and completeness in recording clinical diagnoses and 
prescriptions and provide the ability to update analyses as data 
change over time.30 It is therefore likely to be representative of 
the population of England. It has good face validity since it has 
been conducted in the setting where most patients in the UK are 
assessed, treated and followed up. We have been able to adjust 
for a wide range of confounders based on detailed coded infor-
mation recorded in the patients’ electronic medical record.
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We restricted the sample for these analyses to only include 
patients with hypertension or heart failure so that all patients, 
whether treated with ACE inhibitors/ARBs or not, had the same 
indication for treatment. This is an important additional anal-
ysis as hypertension and heart failure themselves are associated 
with adverse COVID-19 outcomes, and this restricted analysis 
reduces their confounding effect and allows for a more direct 
comparison of the antihypertensive drugs in people with indi-
cations for their use. We also accounted for ethnicity and other 
confounding variables in this restricted analysis which could 
influence the selection of an antihypertensive treatment and 
also be associated with COVID-19 outcomes. Some systematic 
differences are still likely between patients who are treated and 
those who are not, such as severity of hypertension. We have 
carried out an additional analysis where we adjusted for a proxy 
measure of severity.
Limitations
There may be some over- ascertainment of exposure to medica-
tion since our definition was based on issued prescriptions rather 
than dispensed medication. Our analyses focused on drug classes 
rather than individual drugs as there were insufficient cases to 
support an analysis at individual drug level. We have not inves-
tigated the relationship between the intensity and duration of 
exposure and the risk of disease in this early analysis. We investi-
gated the more mechanistically likely and therefore immediately 
clinically important drug associations. Other drug classes can be 
investigated as numbers accrue. Data on community and care 
home deaths or deaths occurring within hospital but not in ICU 
are not yet available from Hospital Episode Statistics and Civil 
Registrations. Linkage of the GP data to national registries of 
outcome data, updated in near real time, will have minimised 
ascertainment bias relating to laboratory confirmed cases. 
However, there will be underascertainment of total COVID-19 
cases due to the current absence of widespread systematic testing 
strategy in the UK, and due to false negative tests. As UK health 
policy during the study period confined testing for COVID-19 
to hospitalised patients, our data focus on the incidence of more 
severe disease, rather than all cases, as most people with prob-
able COVID-19 are not admitted to hospital. Some patients 
deemed to be at high risk of adverse outcomes of COVID-19 
will have self- isolated during our study period to reduce their 
risk of contracting the virus and if effective, may result in a selec-
tion bias with such patients less likely to be become infected and 
subsequently admitted to hospital or ICU. Not all acutely unwell 
patients in hospital are admitted to ICU and this may result in a 
selection bias. Admission to ICU is limited to those who might 
benefit from this treatment and so varies on the basis of patient 
demographic and medical characteristics. Data on deaths in 
ICU were available to us but a significant proportion of patients 
admitted to an ICU were still being treated in an ICU and this 
varied by region as the pandemic spread. For this reason, ICU 
deaths were not included in the analysis. Further analyses of 
mortality will be undertaken once the relevant data (including 
out- of- hospital deaths) become available.
We have undertaken two new novel data linkages by linking 
QResearch to both COVID-19 test results and outcomes 
recorded on the ICNARC CMP data. This new linked data asset 
is a valuable resource for future research projects.
CONCLUSION
In this very large population- based study, ACE inhibitor and ARB 
prescriptions were associated with a reduced risk of COVID-19 
RT- PCR positive disease in a hospital setting adjusting for a wide 
range of demographic factors, potential comorbidities and other 
medication. There was no evidence of an increased or decreased 
risk associated with either drug for ICU admission. There are 
marked variations in risk of COVID-19 disease and ICU admis-
sion by ethnic group, with highest rates among BAME groups. 
The strength of this association is greater with the more severe 
outcome and is not explained by age, sex, deprivation, geograph-
ical region or several comorbidities and intercurrent medications 
included in the analysis. The counterintuitive finding of smokers 
having a lower risk of COVID-19 disease requiring hospital 
admission and ICU admission deserves further study.
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Key messages
What is already known on this subject?
 ► There is uncertainty about the interaction of ACE inhibitor 
and angiotensin receptor blocker (ARB) drugs with COVID-19 
disease susceptibility and disease severity.
What might this study add?
 ► In this very large population- based study, treatment with ACE 
inhibitor and ARB prescriptions is associated with a reduced 
risk of COVID-19 RT- PCR positive disease after adjusting for a 
wide range of variables.
 ► Neither ACE inhibitors nor ARBs are associated with increased 
risks of receiving ICU care for COVID-19 disease.
 ► There are significant interactions with ethnicity for ACE 
inhibitors and ARBs for COVID-19 disease with higher risks 
among the non- white ethnic groups particularly Black African 
patients compared with the white group, although the 
confidence intervals for some analyses are wide; this finding 
is important and adds to existing knowledge.
How might this impact on clinical practice?
 ► Neither ACE inhibitors nor ARBs are associated with increased 
risks of COVID-19 RT- PCR positive disease or of receiving ICU 
care for COVID-19 disease.
 ► Variations between different ethnic groups raise the 
possibility of ethnic- specific effects of ACE inhibitors/ARBs on 
COVID-19 disease susceptibility and severity which deserves 
further study.
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